Prophylactic HIV Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global Prophylactic HIV Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Prophylactic HIV Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Prophylactic HIV Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Prophylactic HIV Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Prophylactic HIV Drug include Merck, Mylan, Roche, Gilead Sciences, Cipla and Bristol-Myers Squibb, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prophylactic HIV Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prophylactic HIV Drug.
The report will help the Prophylactic HIV Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Prophylactic HIV Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Prophylactic HIV Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Prophylactic HIV Drug Segment by Company
Merck Mylan Roche Gilead Sciences Cipla Bristol-Myers SquibbProphylactic HIV Drug Segment by Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Integrase InhibitorProphylactic HIV Drug Segment by Application
Retail Pharmacy Online Pharmacy Hospital PharmacyProphylactic HIV Drug Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Colombia Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic HIV Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prophylactic HIV Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic HIV Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Prophylactic HIV Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Prophylactic HIV Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Prophylactic HIV Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Prophylactic HIV Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Prophylactic HIV Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Prophylactic HIV Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Prophylactic HIV Drug include Merck, Mylan, Roche, Gilead Sciences, Cipla and Bristol-Myers Squibb, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prophylactic HIV Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prophylactic HIV Drug.
The report will help the Prophylactic HIV Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Prophylactic HIV Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Prophylactic HIV Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Prophylactic HIV Drug Segment by Company
Merck Mylan Roche Gilead Sciences Cipla Bristol-Myers SquibbProphylactic HIV Drug Segment by Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Integrase InhibitorProphylactic HIV Drug Segment by Application
Retail Pharmacy Online Pharmacy Hospital PharmacyProphylactic HIV Drug Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Colombia Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic HIV Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prophylactic HIV Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic HIV Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Prophylactic HIV Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Prophylactic HIV Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
116 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Prophylactic HIV Drug Market Size (2020-2031)
- 2.2.2 Global Prophylactic HIV Drug Sales (2020-2031)
- 2.2.3 Global Prophylactic HIV Drug Market Average Price (2020-2031)
- 2.3 Prophylactic HIV Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
- 2.3.3 Integrase Inhibitor
- 2.4 Prophylactic HIV Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Retail Pharmacy
- 2.4.3 Online Pharmacy
- 2.4.4 Hospital Pharmacy
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Prophylactic HIV Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Prophylactic HIV Drug Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global Prophylactic HIV Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global Prophylactic HIV Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global Prophylactic HIV Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Prophylactic HIV Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Prophylactic HIV Drug, Product Type & Application
- 3.8 Global Manufacturers of Prophylactic HIV Drug, Established Date
- 3.9 Global Prophylactic HIV Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Prophylactic HIV Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Merck Prophylactic HIV Drug Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Prophylactic HIV Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Mylan Prophylactic HIV Drug Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Prophylactic HIV Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Roche Prophylactic HIV Drug Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences Prophylactic HIV Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Gilead Sciences Prophylactic HIV Drug Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 Cipla
- 4.5.1 Cipla Company Information
- 4.5.2 Cipla Business Overview
- 4.5.3 Cipla Prophylactic HIV Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Cipla Prophylactic HIV Drug Product Portfolio
- 4.5.5 Cipla Recent Developments
- 4.6 Bristol-Myers Squibb
- 4.6.1 Bristol-Myers Squibb Company Information
- 4.6.2 Bristol-Myers Squibb Business Overview
- 4.6.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolio
- 4.6.5 Bristol-Myers Squibb Recent Developments
- 5 Global Prophylactic HIV Drug Market Scenario by Region
- 5.1 Global Prophylactic HIV Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Prophylactic HIV Drug Sales by Region: 2020-2031
- 5.2.1 Global Prophylactic HIV Drug Sales by Region: 2020-2025
- 5.2.2 Global Prophylactic HIV Drug Sales by Region: 2026-2031
- 5.3 Global Prophylactic HIV Drug Revenue by Region: 2020-2031
- 5.3.1 Global Prophylactic HIV Drug Revenue by Region: 2020-2025
- 5.3.2 Global Prophylactic HIV Drug Revenue by Region: 2026-2031
- 5.4 North America Prophylactic HIV Drug Market Facts & Figures by Country
- 5.4.1 North America Prophylactic HIV Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Prophylactic HIV Drug Sales by Country (2020-2031)
- 5.4.3 North America Prophylactic HIV Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Prophylactic HIV Drug Market Facts & Figures by Country
- 5.5.1 Europe Prophylactic HIV Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Prophylactic HIV Drug Sales by Country (2020-2031)
- 5.5.3 Europe Prophylactic HIV Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Prophylactic HIV Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Prophylactic HIV Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Prophylactic HIV Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Prophylactic HIV Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Prophylactic HIV Drug Market Facts & Figures by Country
- 5.7.1 South America Prophylactic HIV Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Prophylactic HIV Drug Sales by Country (2020-2031)
- 5.7.3 South America Prophylactic HIV Drug Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Prophylactic HIV Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Prophylactic HIV Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Prophylactic HIV Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Prophylactic HIV Drug Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global Prophylactic HIV Drug Sales by Type (2020-2031)
- 6.1.1 Global Prophylactic HIV Drug Sales by Type (2020-2031) & (k units)
- 6.1.2 Global Prophylactic HIV Drug Sales Market Share by Type (2020-2031)
- 6.2 Global Prophylactic HIV Drug Revenue by Type (2020-2031)
- 6.2.1 Global Prophylactic HIV Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Prophylactic HIV Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global Prophylactic HIV Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Prophylactic HIV Drug Sales by Application (2020-2031)
- 7.1.1 Global Prophylactic HIV Drug Sales by Application (2020-2031) & (k units)
- 7.1.2 Global Prophylactic HIV Drug Sales Market Share by Application (2020-2031)
- 7.2 Global Prophylactic HIV Drug Revenue by Application (2020-2031)
- 7.2.1 Global Prophylactic HIV Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Prophylactic HIV Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global Prophylactic HIV Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Prophylactic HIV Drug Value Chain Analysis
- 8.1.1 Prophylactic HIV Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Prophylactic HIV Drug Production Mode & Process
- 8.2 Prophylactic HIV Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Prophylactic HIV Drug Distributors
- 8.2.3 Prophylactic HIV Drug Customers
- 9 Global Prophylactic HIV Drug Analyzing Market Dynamics
- 9.1 Prophylactic HIV Drug Industry Trends
- 9.2 Prophylactic HIV Drug Industry Drivers
- 9.3 Prophylactic HIV Drug Industry Opportunities and Challenges
- 9.4 Prophylactic HIV Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Prophylactic HIV Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Prophylactic HIV Drug Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global Prophylactic HIV Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Prophylactic HIV Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global Prophylactic HIV Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Prophylactic HIV Drug Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global Prophylactic HIV Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Prophylactic HIV Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Prophylactic HIV Drug, Product Type & Application
- Table 14. Global Prophylactic HIV Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Prophylactic HIV Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Merck Company Information
- Table 19. Merck Business Overview
- Table 20. Merck Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. Merck Prophylactic HIV Drug Product Portfolio
- Table 22. Merck Recent Developments
- Table 23. Mylan Company Information
- Table 24. Mylan Business Overview
- Table 25. Mylan Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Mylan Prophylactic HIV Drug Product Portfolio
- Table 27. Mylan Recent Developments
- Table 28. Roche Company Information
- Table 29. Roche Business Overview
- Table 30. Roche Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. Roche Prophylactic HIV Drug Product Portfolio
- Table 32. Roche Recent Developments
- Table 33. Gilead Sciences Company Information
- Table 34. Gilead Sciences Business Overview
- Table 35. Gilead Sciences Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. Gilead Sciences Prophylactic HIV Drug Product Portfolio
- Table 37. Gilead Sciences Recent Developments
- Table 38. Cipla Company Information
- Table 39. Cipla Business Overview
- Table 40. Cipla Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. Cipla Prophylactic HIV Drug Product Portfolio
- Table 42. Cipla Recent Developments
- Table 43. Bristol-Myers Squibb Company Information
- Table 44. Bristol-Myers Squibb Business Overview
- Table 45. Bristol-Myers Squibb Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolio
- Table 47. Bristol-Myers Squibb Recent Developments
- Table 48. Global Prophylactic HIV Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 49. Global Prophylactic HIV Drug Sales by Region (2020-2025) & (k units)
- Table 50. Global Prophylactic HIV Drug Sales Market Share by Region (2020-2025)
- Table 51. Global Prophylactic HIV Drug Sales by Region (2026-2031) & (k units)
- Table 52. Global Prophylactic HIV Drug Sales Market Share by Region (2026-2031)
- Table 53. Global Prophylactic HIV Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 54. Global Prophylactic HIV Drug Revenue Market Share by Region (2020-2025)
- Table 55. Global Prophylactic HIV Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 56. Global Prophylactic HIV Drug Revenue Market Share by Region (2026-2031)
- Table 57. North America Prophylactic HIV Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 58. North America Prophylactic HIV Drug Sales by Country (2020-2025) & (k units)
- Table 59. North America Prophylactic HIV Drug Sales by Country (2026-2031) & (k units)
- Table 60. North America Prophylactic HIV Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 61. North America Prophylactic HIV Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 62. Europe Prophylactic HIV Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 63. Europe Prophylactic HIV Drug Sales by Country (2020-2025) & (k units)
- Table 64. Europe Prophylactic HIV Drug Sales by Country (2026-2031) & (k units)
- Table 65. Europe Prophylactic HIV Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 66. Europe Prophylactic HIV Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 67. Asia Pacific Prophylactic HIV Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 68. Asia Pacific Prophylactic HIV Drug Sales by Country (2020-2025) & (k units)
- Table 69. Asia Pacific Prophylactic HIV Drug Sales by Country (2026-2031) & (k units)
- Table 70. Asia Pacific Prophylactic HIV Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 71. Asia Pacific Prophylactic HIV Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 72. South America Prophylactic HIV Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 73. South America Prophylactic HIV Drug Sales by Country (2020-2025) & (k units)
- Table 74. South America Prophylactic HIV Drug Sales by Country (2026-2031) & (k units)
- Table 75. South America Prophylactic HIV Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 76. South America Prophylactic HIV Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 77. Middle East and Africa Prophylactic HIV Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 78. Middle East and Africa Prophylactic HIV Drug Sales by Country (2020-2025) & (k units)
- Table 79. Middle East and Africa Prophylactic HIV Drug Sales by Country (2026-2031) & (k units)
- Table 80. Middle East and Africa Prophylactic HIV Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 81. Middle East and Africa Prophylactic HIV Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 82. Global Prophylactic HIV Drug Sales by Type (2020-2025) & (k units)
- Table 83. Global Prophylactic HIV Drug Sales by Type (2026-2031) & (k units)
- Table 84. Global Prophylactic HIV Drug Sales Market Share by Type (2020-2025)
- Table 85. Global Prophylactic HIV Drug Sales Market Share by Type (2026-2031)
- Table 86. Global Prophylactic HIV Drug Revenue by Type (2020-2025) & (US$ Million)
- Table 87. Global Prophylactic HIV Drug Revenue by Type (2026-2031) & (US$ Million)
- Table 88. Global Prophylactic HIV Drug Revenue Market Share by Type (2020-2025)
- Table 89. Global Prophylactic HIV Drug Revenue Market Share by Type (2026-2031)
- Table 90. Global Prophylactic HIV Drug Price by Type (2020-2025) & (US$/unit)
- Table 91. Global Prophylactic HIV Drug Price by Type (2026-2031) & (US$/unit)
- Table 92. Global Prophylactic HIV Drug Sales by Application (2020-2025) & (k units)
- Table 93. Global Prophylactic HIV Drug Sales by Application (2026-2031) & (k units)
- Table 94. Global Prophylactic HIV Drug Sales Market Share by Application (2020-2025)
- Table 95. Global Prophylactic HIV Drug Sales Market Share by Application (2026-2031)
- Table 96. Global Prophylactic HIV Drug Revenue by Application (2020-2025) & (US$ Million)
- Table 97. Global Prophylactic HIV Drug Revenue by Application (2026-2031) & (US$ Million)
- Table 98. Global Prophylactic HIV Drug Revenue Market Share by Application (2020-2025)
- Table 99. Global Prophylactic HIV Drug Revenue Market Share by Application (2026-2031)
- Table 100. Global Prophylactic HIV Drug Price by Application (2020-2025) & (US$/unit)
- Table 101. Global Prophylactic HIV Drug Price by Application (2026-2031) & (US$/unit)
- Table 102. Key Raw Materials
- Table 103. Raw Materials Key Suppliers
- Table 104. Prophylactic HIV Drug Distributors List
- Table 105. Prophylactic HIV Drug Customers List
- Table 106. Prophylactic HIV Drug Industry Trends
- Table 107. Prophylactic HIV Drug Industry Drivers
- Table 108. Prophylactic HIV Drug Industry Restraints
- Table 109. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Prophylactic HIV Drug Product Image
- Figure 5. Global Prophylactic HIV Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Prophylactic HIV Drug Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Prophylactic HIV Drug Sales (2020-2031) & (k units)
- Figure 8. Global Prophylactic HIV Drug Average Price (US$/unit) & (2020-2031)
- Figure 9. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Product Image
- Figure 10. Integrase Inhibitor Product Image
- Figure 11. Retail Pharmacy Product Image
- Figure 12. Online Pharmacy Product Image
- Figure 13. Hospital Pharmacy Product Image
- Figure 14. Global Prophylactic HIV Drug Revenue Share by Manufacturers in 2024
- Figure 15. Global Manufacturers of Prophylactic HIV Drug, Manufacturing Sites & Headquarters
- Figure 16. Global Top 5 and 10 Prophylactic HIV Drug Players Market Share by Revenue in 2024
- Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 18. Global Prophylactic HIV Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 19. Global Prophylactic HIV Drug Sales by Region in 2024
- Figure 20. Global Prophylactic HIV Drug Revenue by Region in 2024
- Figure 21. North America Prophylactic HIV Drug Market Size by Country in 2024
- Figure 22. North America Prophylactic HIV Drug Sales Market Share by Country (2020-2031)
- Figure 23. North America Prophylactic HIV Drug Revenue Market Share by Country (2020-2031)
- Figure 24. United States Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 25. Canada Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 26. Mexico Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 27. Europe Prophylactic HIV Drug Market Size by Country in 2024
- Figure 28. Europe Prophylactic HIV Drug Sales Market Share by Country (2020-2031)
- Figure 29. Europe Prophylactic HIV Drug Revenue Market Share by Country (2020-2031)
- Figure 30. Germany Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 31. France Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. U.K. Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. Italy Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Russia Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Spain Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Netherlands Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Switzerland Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Sweden Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Poland Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. Asia Pacific Prophylactic HIV Drug Market Size by Country in 2024
- Figure 41. Asia Pacific Prophylactic HIV Drug Sales Market Share by Country (2020-2031)
- Figure 42. Asia Pacific Prophylactic HIV Drug Revenue Market Share by Country (2020-2031)
- Figure 43. China Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Japan Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. South Korea Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. India Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. Australia Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Taiwan Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Southeast Asia Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. South America Prophylactic HIV Drug Market Size by Country in 2024
- Figure 52. South America Prophylactic HIV Drug Sales Market Share by Country (2020-2031)
- Figure 53. South America Prophylactic HIV Drug Revenue Market Share by Country (2020-2031)
- Figure 54. Brazil Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Argentina Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Chile Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. Colombia Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 58. Middle East and Africa Prophylactic HIV Drug Market Size by Country in 2024
- Figure 59. Middle East and Africa Prophylactic HIV Drug Sales Market Share by Country (2020-2031)
- Figure 60. Middle East and Africa Prophylactic HIV Drug Revenue Market Share by Country (2020-2031)
- Figure 61. Egypt Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 62. South Africa Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 63. Israel Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 64. Türkiye Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 65. GCC Countries Prophylactic HIV Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 66. Global Prophylactic HIV Drug Sales Market Share by Type (2020-2031)
- Figure 67. Global Prophylactic HIV Drug Revenue Market Share by Type (2020-2031)
- Figure 68. Global Prophylactic HIV Drug Price (US$/unit) by Type (2020-2031)
- Figure 69. Global Prophylactic HIV Drug Sales Market Share by Application (2020-2031)
- Figure 70. Global Prophylactic HIV Drug Revenue Market Share by Application (2020-2031)
- Figure 71. Global Prophylactic HIV Drug Price (US$/unit) by Application (2020-2031)
- Figure 72. Prophylactic HIV Drug Value Chain
- Figure 73. Prophylactic HIV Drug Production Mode & Process
- Figure 74. Direct Comparison with Distribution Share
- Figure 75. Distributors Profiles
- Figure 76. Prophylactic HIV Drug Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
